SCHEMBL18293293

SCHEMBL18293293

CC(C)(C)OC(=O)N1CCc2c(sc(NC(=O)CCNC3CC4CN(C(=O)OC(C)(C)C)CC4C3)c2-c2nc3cc(Br)ccc3s2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 2/20 0.47
NPC1 O15118 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MYC P01106 4/20 0.45
TP53 P04637 2/20 0.43
MEN1 O00255 2/20 0.43
HTT P42858 2/20 0.43
KMT2A Q03164 2/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
FABP4 P15090 1/20 0.42
FABP5 Q01469 1/20 0.42
APEX1 P27695 4/20 0.42
LMNA P02545 3/20 0.40
MKNK1 Q9BUB5 1/20 0.39
UHRF1 Q96T88 1/20 0.39
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20240042 1.00 MAPT (0.47) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL20240041 1.00 MAPT (0.47) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL30406967 1.00 MAPT (0.47) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL20239953 0.97 MAPT (0.45) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL22449464 0.97 MAPT (0.45) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL22449465 0.97 MAPT (0.45) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL20239938 0.91 MAPT (0.58) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL20254258 0.91 MAPT (0.58) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL20239939 0.91 MAPT (0.58) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL18293291 0.91 MAPT (0.58) MAPTKDM4EALDH1A1NPC1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
WO-2016197078-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS, INC. (US) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 MAPT 131/4885KDM4E 4623/4885ALDH1A1 2768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.